Shaily Engineering Plastics Limited has informed the Exchange about Presentation
SHAILY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Shaily Engineering Plastics reported strong FY26 results with consolidated revenue of Rs. 990.7 crore (up 26% YoY) and PAT of Rs. 169.9 crore (up 83% YoY). EBITDA margins improved significantly to 29.0% from 22.7% in FY25. Healthcare emerged as the key growth driver with revenue jumping 139% to Rs. 392.8 crore, fueled by a Rs. 423 crore pen injector order from a large domestic pharma company over four years and commercial launches of Semaglutide pens. Consumer segment faced headwinds due to weak European and US demand for home furnishings, declining 9% to Rs. 511.3 crore. The company also entered the semiconductor supply chain via a partnership with a Korean company. The Board approved an enabling resolution for raising up to Rs. 500 crore through equity or convertible instruments.
The substantial margin improvement and healthcare segment momentum signal a successful business transformation toward higher-margin products. However, the consumer segment weakness and upcoming fund raise could create near-term dilution concerns. The strong order backlog provides revenue visibility for the healthcare segment.